Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders

Yang Liu¹, Wery P M van den Wildenberg², Ysanne de Graaf³, Susan L Ames⁴, Alexander Baldacchino⁵, Ragnhild Bø⁶, Fernando Cadaveira⁷, Salvatore Campanella⁸, Paul Christiansen⁹, Eric D Claus¹⁰, Lorenza S Colzato¹¹, Francesca M Filbey¹², John J Foxe¹³, Hugh Garavan¹⁴, Christian S Hendershot¹⁵, Robert Hester¹⁶, Jennifer M Jester¹⁷, Hollis C Karoly¹⁸, Anja Kräplin¹⁹, Fanny Kreusch²⁰, Nils Inge Landrø⁶, Marianne Littel²¹, Sabine Loeber²², Edythe D London²³, Eduardo López-Caneda²⁴, Dan I Lubman²⁵, Maartje Luijten²⁶, Cecile A Marczinski²⁷, Jane Metrik²⁸, Catharine Montgomery²⁹, Harilaos Papachristou³⁰, Su Mi Park³¹, Andres L Paz³², Géraldine Petit⁹, James J Prisciandaro³³, Boris B Quednow³⁴, Lara A Ray³⁵, Carl A Roberts⁹, Gloria M P Roberts³⁶, Michiel B de Ruiter³⁷, Claudia I Rupp³⁸, Vaughn R Steele¹⁰, Delin Sun³⁹, Michael Takagi⁴⁰, Susan F Tapert⁴¹, Ruth J van Holst⁴², Antonio Verdejo-Garcia⁴³, Matthias Vonmoos³⁴, Marcin Wojnar⁴⁴, Yuanwei Yao⁴⁵, Murat Yücel⁴⁶, Martin Zack⁴⁷, Robert A Zucker¹⁷, Hilde M Huizenga⁴⁸, Reinout W Wiers⁴⁹

Affiliations

¹ Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Addiction, Development, and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: liu.yang.ocean1@gmail.com.
² Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition Center, University of Amsterdam, Amsterdam, the Netherlands.
³ Faculty of Science (FNWI), University of Amsterdam, Amsterdam, the Netherlands.
⁴ School of Community and Global Health, Claremont Graduate University, Claremont, CA, USA.
⁵ Division of Population and Behavioural Sciences, St Andrews University Medical School, University of St Andrews, St Andrews, Scotland, UK.
⁶ Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway.
⁷ Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Galicia, Spain.
⁸ Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
⁹ Department of Psychological Sciences, University of Liverpool, Liverpool, UK.
¹⁰ The Mind Research Network and Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM, USA.
¹¹ Leiden University, Cognitive Psychology Unit & Leiden Institute for Brain and Cognition, Leiden, the Netherlands.
¹² Center for BrainHealth, School of Behavioral and Brain Sciences, The University of Texas at Dallas, TX, USA.
¹³ University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, USA.
¹⁴ Department of Psychiatry, University of Vermont, Burlington, USA.
¹⁵ Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute and Institute for Mental Health Policy Research, Toronto, Canada.
¹⁶ School of Psychological Sciences, University of Melbourne, Melbourne, Australia.
¹⁷ Department of Psychiatry, University of Michigan, MI, USA.
¹⁸ Institute of Cognitive Science, University of Colorado Boulder, CO, USA.
¹⁹ Work Group Addictive Behaviours, Risk Analyses and Risk Management, Faculty of Psychologie, Technische Universität Dresden, Germany.
²⁰ Department of Psychology, University of Liège, Belgium.
²¹ Department of Psychology, Erasmus University Rotterdam, Rotterdam, the Netherlands.
²² Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.
²³ Department of Psychiatry and Biobehavioral Sciences at the University of California, Los Angeles, USA.
²⁴ Psychological Neuroscience Lab, Research Center in Psychology (CIPsi), School of Psychology, University of Minho, Braga, Portugal.
²⁵ Turning Point, Eastern Health and Eastern Health Clinical School, Monash University, Melbourne, Australia.
²⁶ Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands.
²⁷ Northern Kentucky University, Highland Heights, USA.
²⁸ Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, USA.
²⁹ School of Natural Sciences and Psychology, Liverpool John Moores University, Liverpool, UK.
³⁰ Maastricht University, Faculty of Psychology and Neuroscience, the Netherlands.
³¹ Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea; Department of Clinical Medical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
³² Department of Psychology, Charles Schmidt College of Science, Florida Atlantic University, USA.
³³ Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
³⁴ Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.
³⁵ University of California Los Angeles, Department of Psychology, Los Angeles, CA, USA.
³⁶ School of Psychiatry, University of New South Wales, Sydney, Australia.
³⁷ Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
³⁸ Department of Psychiatry, Psychotherapy and Psychosomatic, Medical University Innsbruck, Austria.
³⁹ Duke Brain Imaging and Analysis Center, Duke University School of Medicine, Durham, NC, USA; Mid-Atlantic Mental Illness Research, Education and Clinical Center (MIRECC), Durham, NC, USA.
⁴⁰ Child Neuropsychology Research Group, Murdoch Children's Research Institute, Melbourne, Australia; Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia.
⁴¹ Department of Psychiatry, University of California, San Diego, USA.
⁴² Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Institute for Addiction Research, Amsterdam, the Netherlands.
⁴³ Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.
⁴⁴ Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland.
⁴⁵ State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.
⁴⁶ School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash Biomedical Imaging Facility, Monash University, Melbourne, Victoria, Australia.
⁴⁷ Molecular Brain Science Research Section Centre for Addiction and Mental Health, Toronto, Canada.
⁴⁸ Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition Center, University of Amsterdam, Amsterdam, the Netherlands; Research Priority Area Yield, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands.
⁴⁹ Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Addiction, Development, and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands.

PMID: 31319124
DOI: 10.1016/j.neubiorev.2019.07.006

Free article

Review

Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders

Yang Liu et al. Neurosci Biobehav Rev. 2019 Oct.

Free article

. 2019 Oct:105:288-304.

doi: 10.1016/j.neubiorev.2019.07.006. Epub 2019 Jul 15.

Authors

Affiliations

¹ Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Addiction, Development, and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: liu.yang.ocean1@gmail.com.
² Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition Center, University of Amsterdam, Amsterdam, the Netherlands.
³ Faculty of Science (FNWI), University of Amsterdam, Amsterdam, the Netherlands.
⁴ School of Community and Global Health, Claremont Graduate University, Claremont, CA, USA.
⁵ Division of Population and Behavioural Sciences, St Andrews University Medical School, University of St Andrews, St Andrews, Scotland, UK.
⁶ Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway.
⁷ Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Galicia, Spain.
⁸ Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
⁹ Department of Psychological Sciences, University of Liverpool, Liverpool, UK.
¹⁰ The Mind Research Network and Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM, USA.
¹¹ Leiden University, Cognitive Psychology Unit & Leiden Institute for Brain and Cognition, Leiden, the Netherlands.
¹² Center for BrainHealth, School of Behavioral and Brain Sciences, The University of Texas at Dallas, TX, USA.
¹³ University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, USA.
¹⁴ Department of Psychiatry, University of Vermont, Burlington, USA.
¹⁵ Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute and Institute for Mental Health Policy Research, Toronto, Canada.
¹⁶ School of Psychological Sciences, University of Melbourne, Melbourne, Australia.
¹⁷ Department of Psychiatry, University of Michigan, MI, USA.
¹⁸ Institute of Cognitive Science, University of Colorado Boulder, CO, USA.
¹⁹ Work Group Addictive Behaviours, Risk Analyses and Risk Management, Faculty of Psychologie, Technische Universität Dresden, Germany.
²⁰ Department of Psychology, University of Liège, Belgium.
²¹ Department of Psychology, Erasmus University Rotterdam, Rotterdam, the Netherlands.
²² Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.
²³ Department of Psychiatry and Biobehavioral Sciences at the University of California, Los Angeles, USA.
²⁴ Psychological Neuroscience Lab, Research Center in Psychology (CIPsi), School of Psychology, University of Minho, Braga, Portugal.
²⁵ Turning Point, Eastern Health and Eastern Health Clinical School, Monash University, Melbourne, Australia.
²⁶ Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands.
²⁷ Northern Kentucky University, Highland Heights, USA.
²⁸ Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, USA.
²⁹ School of Natural Sciences and Psychology, Liverpool John Moores University, Liverpool, UK.
³⁰ Maastricht University, Faculty of Psychology and Neuroscience, the Netherlands.
³¹ Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea; Department of Clinical Medical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
³² Department of Psychology, Charles Schmidt College of Science, Florida Atlantic University, USA.
³³ Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
³⁴ Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.
³⁵ University of California Los Angeles, Department of Psychology, Los Angeles, CA, USA.
³⁶ School of Psychiatry, University of New South Wales, Sydney, Australia.
³⁷ Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
³⁸ Department of Psychiatry, Psychotherapy and Psychosomatic, Medical University Innsbruck, Austria.
³⁹ Duke Brain Imaging and Analysis Center, Duke University School of Medicine, Durham, NC, USA; Mid-Atlantic Mental Illness Research, Education and Clinical Center (MIRECC), Durham, NC, USA.
⁴⁰ Child Neuropsychology Research Group, Murdoch Children's Research Institute, Melbourne, Australia; Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia.
⁴¹ Department of Psychiatry, University of California, San Diego, USA.
⁴² Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Institute for Addiction Research, Amsterdam, the Netherlands.
⁴³ Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.
⁴⁴ Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland.
⁴⁵ State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.
⁴⁶ School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash Biomedical Imaging Facility, Monash University, Melbourne, Victoria, Australia.
⁴⁷ Molecular Brain Science Research Section Centre for Addiction and Mental Health, Toronto, Canada.
⁴⁸ Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition Center, University of Amsterdam, Amsterdam, the Netherlands; Research Priority Area Yield, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands.
⁴⁹ Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Addiction, Development, and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands.

PMID: 31319124
DOI: 10.1016/j.neubiorev.2019.07.006

Abstract

Many studies have reported that heavy substance use is associated with impaired response inhibition. Studies typically focused on associations with a single substance, while polysubstance use is common. Further, most studies compared heavy users with light/non-users, though substance use occurs along a continuum. The current mega-analysis accounted for these issues by aggregating individual data from 43 studies (3610 adult participants) that used the Go/No-Go (GNG) or Stop-signal task (SST) to assess inhibition among mostly "recreational" substance users (i.e., the rate of substance use disorders was low). Main and interaction effects of substance use, demographics, and task-characteristics were entered in a linear mixed model. Contrary to many studies and reviews in the field, we found that only lifetime cannabis use was associated with impaired response inhibition in the SST. An interaction effect was also observed: the relationship between tobacco use and response inhibition (in the SST) differed between cannabis users and non-users, with a negative association between tobacco use and inhibition in the cannabis non-users. In addition, participants' age, education level, and some task characteristics influenced inhibition outcomes. Overall, we found limited support for impaired inhibition among substance users when controlling for demographics and task-characteristics.

Keywords: Go/No-Go task; Mega-analysis; Polysubstance use; Response inhibition; Stop-signal task.

PubMed Disclaimer

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

R01 DA021403/DA/NIDA NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect - Access expert opinions and insights on biomedical research.
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders

Affiliations

Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical